Substance and claimed effects

Menopausal hormone therapy (MHT, historically called HRT) replaces the estrogen — and, when the uterus is intact, the progestogen — that ovarian failure withdraws around age 51. The pharmacological backbone is estradiol or conjugated equine estrogen, delivered orally, transdermally (patch / gel / spray), or vaginally (cream / tablet / ring), paired with a progestogen (oral micronized progesterone, levonorgestrel IUD, or a synthetic progestin) in women with a uterus to oppose endometrial proliferation. Claimed and evidence-supported effects, all in scope for this entry: substantial relief of vasomotor symptoms (hot flashes, night sweats) — the dominant indication MacLennan 2004; reversal of the genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTI, urgency) via systemic or low-dose vaginal estrogen NAMS GSM 2020; prevention of osteoporotic fracture Cauley 2003; modulation of cardiovascular disease risk that depends critically on timing of initiation — the timing hypothesis: protective if started within ~10 years of menopause or before age 60, neutral-to-harmful if started later Rossouw 2007 Hodis 2016 Manson 2017; breast cancer risk modulation that diverges sharply by regimen — estrogen alone (in hysterectomized women) reduces incidence, estrogen plus progestin increases it modestly Chlebowski 2020; sleep, mood, and quality-of-life improvements largely secondary to vasomotor relief; and cognitive outcomes that hinge on age of initiation — neutral or possibly protective near menopause, harmful when started in women aged 65+ Shumaker 2003 Henderson 2016. The FDA in 2025 convened an expert panel and announced reconsideration of the boxed warning that has sat on systemic MHT products since 2003 — the regulatory acknowledgement that the WHI's class-warning approach, derived from women a median 12 years past menopause, has been applied to women for whom it was never appropriate FDA 2025 Manson 2024.

Evidence by addressing question

mechanism

Estradiol is the dominant ovarian estrogen during reproductive life. Ovarian follicular depletion at menopause drops circulating estradiol from a cycling range of ~50–400 pg/mL to ~5–20 pg/mL. Estrogen receptors (ERα, ERβ, and the membrane GPER) sit on virtually every tissue: hypothalamic thermoregulatory neurons in the preoptic area, urogenital epithelium, osteoblasts and osteoclasts, vascular endothelium and smooth muscle, hippocampal and prefrontal neurons, mammary epithelium Mehta 2021. Withdrawal produces the canonical menopausal syndrome via three mechanisms: dysregulation of the hypothalamic temperature set-point (driven by hyperactivity of KNDy — kisspeptin/neurokinin B/dynorphin — neurons unopposed by estrogen), producing vasomotor symptoms; atrophy of estrogen-dependent epithelia (vaginal, urethral, trigonal), producing GSM; and an accelerated phase of bone resorption as estrogen restraint on osteoclast activity is lifted, producing 1–3% annual bone loss for the first 5–10 postmenopausal years NAMS 2022.

Cardiovascular mechanism is regimen- and timing-dependent. In recently menopausal arteries, estradiol promotes endothelial nitric oxide, improves lipid profile (LDL ↓, HDL ↑), and inhibits early atherosclerotic plaque formation — the basis of the "healthy endothelium hypothesis." In arteries already laden with established, possibly unstable plaque (typical of women a decade or more past menopause), estrogen's prothrombotic and pro-inflammatory effects on vulnerable plaque can precipitate events, especially in the first 1–2 years of treatment Hodis 2016 Rossouw 2007. Oral estrogen is metabolized through the liver and raises clotting factors and triglycerides; transdermal estrogen bypasses first-pass hepatic metabolism and confers minimal-to-no excess venous thromboembolism risk in observational data Canonico 2007. The progestogen component matters: medroxyprogesterone acetate (the WHI synthetic, MPA) appears to drive most of the combined-arm's breast cancer signal and may oppose some of estrogen's vascular benefit; micronized progesterone and the levonorgestrel IUD have more favourable profiles in observational data, though no head-to-head mortality RCT exists NAMS 2022 CGHFBC 2019.

evidence

Vasomotor symptoms. The most settled signal in the literature. Cochrane meta-analysis of 24 placebo-controlled RCTs found systemic estrogen reduced hot-flash frequency by ~75% (weighted mean ~18 fewer flushes per week) and severity by similar magnitudes versus placebo MacLennan 2004. Effect sizes are larger than any non-hormonal alternative (SSRIs, gabapentin, oxybutynin, fezolinetant) on a head-to-head basis Stuenkel 2015 NAMS 2022.

Bone. WHI estrogen-plus-progestin reduced clinical fractures by HR 0.76 (95% CI 0.69–0.85) and hip fractures by HR 0.67 — the only therapy that has reduced fractures in a low-risk population in a primary-prevention RCT Cauley 2003. The estrogen-alone arm produced similar reductions Anderson 2004. The effect attenuates within 2–5 years of stopping, so MHT is bone-protective while taken and largely not after.

Genitourinary syndrome of menopause. Low-dose vaginal estrogen (cream, tablet, ring) restores epithelial thickness, vaginal pH, and lubrication; reduces dyspareunia and recurrent UTI; with serum estradiol levels at or below the postmenopausal baseline. NAMS 2020 GSM position statement: vaginal estrogen carries none of the systemic-MHT risk profile and the boxed warning class-extended to vaginal products has never had supporting trial data NAMS GSM 2020.

Cardiovascular — the timing hypothesis. WHI E+P (n=16,608, mean age 63, median 12 years past menopause) reported HR 1.29 for coronary heart disease, prompting the 2002 trial halt and the boxed warning Rossouw 2002. Subsequent age-stratified re-analysis showed the CHD signal was driven entirely by women in the 70–79 age stratum; women within 10 years of menopause had HR 0.76 (non-significant) Rossouw 2007. The Danish DOPS RCT (n=1006, recently menopausal women, 10-year follow-up) reported a 52% reduction in the composite of death, MI, and heart failure (HR 0.48, 95% CI 0.26–0.87) with no excess cancer or stroke Schierbeck 2012. ELITE (n=643) randomized women by stratified time-since-menopause; the early-stratum (<6 years) showed slowed carotid intima-media thickness progression with oral estradiol vs placebo; the late-stratum (≥10 years) showed no benefit — the strongest mechanistic confirmation of timing Hodis 2016. KEEPS (n=727, oral CEE or transdermal estradiol, 4 years) found no atherosclerosis progression difference vs placebo in any arm but improved quality of life and lipid markers Harman 2014. Cochrane 2015 stratified meta-analysis found women starting MHT <10 years from menopause had a 48% reduction in coronary deaths and MI (RR 0.52, 95% CI 0.29–0.96) and 30% all-cause mortality reduction Boardman 2015. WHI 18-year cumulative follow-up: no statistically significant difference in all-cause or cause-specific mortality versus placebo across either arm, but in women initiating at 50–59 the point estimate trended favourable for all-cause mortality Manson 2017.

Breast cancer — regimen-dependent. In WHI's estrogen-plus-progestin arm: HR 1.24 for invasive breast cancer (5.6 years intervention), persistent at long-term follow-up but with HR for breast-cancer mortality 1.45 — modest absolute increase (~1 extra case per 1000 women per year over baseline) Chlebowski 2020. In the estrogen-alone arm (hysterectomized women, conjugated equine estrogen): HR 0.78 for breast cancer incidence and HR 0.60 for breast cancer mortality — a statistically significant reduction Anderson 2004 Chlebowski 2020. The CGHFBC individual-participant meta-analysis (n>500,000) replicated the directional finding: 5 years of E+P from age 50 produces ~8.3% lifetime breast cancer risk vs 6.3% in never-users (an excess of ~1 per 50 over 20 years); estrogen-alone produces a smaller excess (~1 per 200) CGHFBC 2019. The Million Women Study reported a larger E+P risk (RR ~2.0 for current users) but is observational and likely biased by detection and confounding Beral 2003. The author's call below addresses the gap.

Cognition. WHIMS (substudy of WHI, women aged 65+ at initiation): E+P doubled dementia incidence (HR 2.05) and increased mild cognitive impairment — the strongest argument against late initiation Shumaker 2003. WHIMSY (women initiated in WHI at 50–55, cognition assessed at 7-year follow-up): no harm and no benefit on cognition Espeland 2013. ELITE-Cog (early- vs late-onset estradiol, 5-year cognitive battery): neutral in both strata Henderson 2016. Mayo cohort: women who underwent bilateral oophorectomy before age 45 without estrogen replacement showed a hazard ratio of ~1.7 for cognitive impairment and dementia compared with referents — the strongest evidence that estrogen withdrawal in premature menopause is cognitively costly, and that replacement until natural menopause age (~51) is protective in this group Rocca 2007.

Mortality. Bayesian meta-analysis of women starting MHT <60 (n=8,400 across 19 trials): odds ratio 0.61 for all-cause mortality (95% CI 0.39–0.95) Salpeter 2009. Finnish national registry (n>500,000 women who used MHT): discontinuation associated with increased cardiac and stroke mortality, especially in users <60 stopping abruptly Mikkola 2015. WHI long-term: no all-cause mortality signal either direction at 18 years Manson 2017.

protocol

The 2022 NAMS position statement (the field's reference guideline) frames MHT as appropriate first-line therapy for symptomatic women under 60 or within 10 years of menopause, with shared decision-making documenting personal risk factors. Standard systemic regimens: oral conjugated equine estrogen 0.3–0.625 mg/day, oral estradiol 0.5–1.0 mg/day, transdermal estradiol patch 25–100 μg twice weekly, or gel/spray equivalents NAMS 2022 Stuenkel 2015. Transdermal route is preferred when VTE risk is non-trivial (BMI >30, prior VTE in family, age 60+), migraine with aura, hypertriglyceridemia, or active gallbladder disease Canonico 2007. Women with intact uterus require a progestogen: micronized progesterone 100 mg nightly (continuous-combined) or 200 mg for 12 days each month (sequential, often preferred in perimenopause). The levonorgestrel-releasing IUD is an off-label but increasingly accepted alternative for endometrial protection. Vaginal estrogen for GSM uses doses 5–10% of systemic with serum levels at or below postmenopausal baseline; can be combined with systemic MHT or used alone NAMS GSM 2020. Duration: NAMS 2022 explicitly rejects arbitrary stopping at 5 years — continuation should reflect ongoing risk-benefit, with no fixed ceiling; many symptomatic women benefit through their 60s and into their 70s if started early.

contraindications

Absolute contraindications to systemic MHT (NAMS, Endocrine Society, ACOG consistent): personal history of breast cancer, history of estrogen-sensitive cancer, history of venous thromboembolism or pulmonary embolism, history of stroke or myocardial infarction, active liver disease, unexplained vaginal bleeding, known or suspected pregnancy NAMS 2022 Stuenkel 2015. Relative contraindications: high baseline cardiovascular risk (consider transdermal), uncontrolled hypertension, gallbladder disease, hypertriglyceridemia, migraine with aura. Vaginal estrogen has a markedly narrower contraindication profile — the NAMS GSM statement notes safety even in breast cancer survivors after discussion with oncologist NAMS GSM 2020. The FDA 2025 announcement of boxed-warning reconsideration explicitly recognizes the class-extension problem: the warnings derived from WHI's older-mean-age systemic-CEE/MPA cohort have been applied to low-dose vaginal estrogen with no supporting evidence FDA 2025.

misconceptions

• "HRT causes breast cancer." Combined E+P modestly increases risk (~1 extra case per 1000 women per year). Estrogen-alone in hysterectomized women decreases breast cancer incidence and mortality Anderson 2004 Chlebowski 2020. The distinction is regularly elided in public messaging.
• "HRT causes heart attacks." Initiated within 10 years of menopause, MHT reduces coronary events and all-cause mortality. Initiated 20 years out in women with existing atherosclerosis, it raises early-period event risk Rossouw 2007 Hodis 2016 Boardman 2015.
• "HRT has to stop at 5 years." NAMS 2022 explicitly rejects this — duration is individualized to risk-benefit, with no fixed limit NAMS 2022.
• "Bioidentical compounded hormones are safer than FDA-approved MHT." No RCT evidence; compounded preparations lack dose verification and have been associated with endometrial hyperplasia in surveillance reports NAMS 2022.
• "Vaginal estrogen carries the same risks as systemic." Serum levels with low-dose vaginal estrogen sit at or below postmenopausal baseline; the boxed warning class-extended to these products has no supporting trial data NAMS GSM 2020 FDA 2025.
• "Hot flashes are just hot flashes — wait them out." Median duration is 7.4 years (the SWAN study); the women hardest hit (African American, early-onset symptom profile) average over 10 years NAMS 2022. Untreated vasomotor symptoms also correlate with cardiovascular endpoints in observational data, though causality is unclear.

audience

Population narrowing: all women in or past the menopausal transition. The strongest case for systemic MHT: women 40–59 within 10 years of menopause with bothersome vasomotor symptoms, GSM, or established osteopenia, no contraindications. Premature menopause (natural or surgical <45): systemic MHT recommended until at least age 51 by all major guidelines — withdrawal in this window is cardiovascularly and cognitively costly Rocca 2007 NAMS 2022. Late menopause (60+ initiation) where symptoms persist: case-by-case, transdermal preferred, lowest effective dose. Hysterectomized women: estrogen-alone, no progestogen needed, with the most favourable risk-benefit ratio of any MHT regimen in WHI data Anderson 2004. GSM alone: any age, low-dose vaginal estrogen, no contraindications except breast cancer history (and even there, after discussion with oncologist) NAMS GSM 2020.

failure-modes

• Late initiation in symptomatic but high-risk women. The single biggest failure mode in the post-WHI era: women suffered through 5–10 years of vasomotor symptoms, then asked for MHT at age 65+ with established atherosclerosis, where the risk-benefit had genuinely flipped Manson 2024.
• Wrong progestogen or no progestogen in a uterus-intact woman. Endometrial hyperplasia and cancer risk; the reason the FDA mandated combined regimens.
• Compounded "bioidentical" preparations. Dose unverifiable; surveillance evidence of endometrial complications NAMS 2022.
• Wrong route in high-VTE-risk women. Oral estrogen in a BMI 35 woman with prior superficial thrombophlebitis — transdermal is the correct choice and is often missed Canonico 2007.
• Abrupt discontinuation. Vasomotor rebound is common and severe; the Finnish registry data also flags excess cardiac mortality in the first year after abrupt withdrawal in women <60 Mikkola 2015.
• Under-dosing for symptom control. Standard-dose estradiol 0.5 mg often inadequate; titration to 1 mg or higher is appropriate when symptoms persist.

practicalities

Cost: generic oral estradiol and transdermal patch run roughly $10–40/month with insurance coverage in the US; brand-name combinations and bioidentical creams can run $100–300/month. Vaginal estrogen tablets and rings cost $50–250/month at list price, lower with insurance. Requires a prescriber — typically gynecologist, primary care physician, or menopause-certified clinician (NAMS Certified Menopause Practitioner directory). Initial visit, baseline mammogram and pelvic exam, optional baseline bone density. Follow-up at 3 months for dose titration, then annually. The structural friction is access: many primary care physicians trained during the 2002–2017 WHI-fear era are still reluctant to initiate MHT, and a menopause-fluent prescriber may take referral or self-pay Manson 2024.

history

Conjugated equine estrogen (Premarin) was approved in 1942 for vasomotor symptoms. By the 1990s, systemic MHT was the most prescribed drug class in postmenopausal American women, on the basis of observational data suggesting cardiovascular protection. The WHI (launched 1991, E+P arm halted 2002, E-alone arm halted 2004) was the first large RCT and reported the headline risks that triggered the 2003 FDA boxed warning Rossouw 2002 Anderson 2004. US prescriptions fell ~80% within two years. The 2007 age-stratified WHI re-analysis introduced the "timing hypothesis" Rossouw 2007; DOPS (2012), KEEPS (2014), ELITE (2016), and Manson's 18-year mortality follow-up (2017) progressively rehabilitated MHT for the early-postmenopausal population Schierbeck 2012 Harman 2014 Hodis 2016 Manson 2017. NAMS 2022 marked the formal pivot of the US menopause field NAMS 2022. The 2025 FDA expert panel and announced boxed-warning reconsideration is the regulatory acknowledgement that the warning, derived from a population with a median age of 63, was inappropriately class-extended FDA 2025 Manson 2024.

stakes

For the symptomatic 51-year-old who does not get MHT: a median 7.4 years of multiple-daily hot flashes and night sweats, fractured sleep, mood disruption, work-performance disruption, partner-relationship strain — the SWAN cohort confirms this is the modal experience NAMS 2022. GSM is progressive and does not remit: vaginal dryness, dyspareunia, recurrent UTI compound through the 60s and 70s. Bone loss during the menopausal transition is irreversible without intervention; women who lose 15% of femoral neck BMD in the first decade are on a different fracture trajectory at 80. The cardiovascular and dementia trajectories that an unreplaced premature/surgical menopause produces are documented and substantial Rocca 2007.

payoff

Vasomotor symptom relief is felt within 2–4 weeks of starting an adequate dose; sleep stabilizes by week 4–6; GSM (especially with vaginal estrogen) reverses by 4–12 weeks. Bone preservation is a multi-year accrual — net positive BMD trajectory measurable at 12–24 months. Cardiovascular benefit (in the early-initiator population) accumulates over years and shows up in the 10-year follow-up endpoints of DOPS and the 18-year Manson follow-up Schierbeck 2012 Manson 2017. Cognitive trajectory protection in surgical/premature menopause is multi-decade Rocca 2007. Mood and quality-of-life lift tracks vasomotor relief; the SSRI-class non-hormonal alternatives do not produce comparable global quality-of-life gains MacLennan 2004.

out-of-scope

Non-hormonal vasomotor therapies (SSRI/SNRI, gabapentin, oxybutynin, fezolinetant) — separate substances, separate entries. Testosterone supplementation for hypoactive sexual desire disorder in postmenopausal women — distinct intervention with thin evidence outside the libido endpoint. DHEA, tibolone (not available in US), and selective estrogen receptor modulators (raloxifene, ospemifene) — adjacent but separate. Lifestyle measures (cooling, layered clothing, weight management) — relevant adjunct but not what this entry covers. Bone-specific therapies (bisphosphonates, denosumab) — separate. Cognitive aging and dementia prevention generally — relevant only insofar as MHT timing modulates it.

The credibility range

Optimist case

For the typical reader — a woman 45–60 in or past the menopausal transition, symptomatic, without contraindications — MHT is one of the highest-value interventions in medicine: dominant relief of the dominant symptom (~75% hot-flash reduction), prevention of an osteoporotic fracture trajectory, reversal of GSM, plausible cardiovascular benefit when started early, plausible cognitive-trajectory benefit in premature menopause, plausible all-cause mortality benefit in the <60-at-initiation cohort. The WHI's headline risk numbers were derived from a population (mean age 63, median 12 years past menopause) that does not match the population now being treated; the post-2007 timing-stratified data is consistent across DOPS, ELITE, KEEPS, and the Cochrane stratified meta-analysis. The breast cancer signal is real but small in absolute terms (~1 case per 1000 women per year for combined therapy) and is reduced, not increased, by estrogen-alone in hysterectomized women. The boxed warning has produced two decades of preventable suffering — millions of women under-treated for vasomotor symptoms, accumulated bone loss, ongoing GSM, partner-relationship and career impact — for a population in which the risk-benefit was favourable. The 2025 FDA action acknowledges the error FDA 2025 Manson 2024.

Skeptic case

The timing-hypothesis evidence is observational re-analysis plus modest-sized RCTs (DOPS n=1006, ELITE n=643) that were not designed for hard cardiovascular endpoints. WHI itself, even age-stratified, did not show a statistically significant CHD reduction in the early-postmenopausal group — the favourable estimate is suggestive, not proven. The breast cancer increase with E+P is small but real and accumulates with duration; the CGHFBC meta-analysis showed risk continuing to elevate through 10+ years of use and persisting after stopping. WHI long-term follow-up: no all-cause mortality benefit either direction at 18 years Manson 2017. The "timing hypothesis" risks becoming a permission structure for indefinite MHT in healthy women who would otherwise pass through menopause with manageable symptoms; observational confounding (healthy-user bias, socioeconomic gradient) probably inflates the apparent benefit in early-postmenopausal cohorts. Commercial incentives are non-trivial: a large pharmaceutical market, a menopause-clinic industry, multiple consumer-facing brands. Vaginal estrogen for GSM is solidly evidenced and uncontroversial in current debate; the systemic-MHT enthusiasm has run ahead of trial data for hard endpoints.

Author's call

Land on the optimist side, with strong calibration. For symptomatic women under 60 or within 10 years of menopause without contraindications, MHT is appropriate first-line therapy and the field's two-decade reluctance was a regulatory error compounded by clinician training. The 2025 FDA action and NAMS 2022 position represent the genuine recalibration. For asymptomatic women, the case is weaker — bone-preservation alone does not earn an indefinite hormone prescription if the woman can do resistance training and adequate calcium/vitamin D. For women past 60 or 10 years out, the timing case has flipped and initiation is generally inappropriate. For vaginal estrogen specifically (GSM), the entry's recommendation is strong and uncontested in the literature; the FDA boxed warning on local products was never supported by trial data. Evidence rating: 4 — strong RCT base on symptoms, bone, and breast (WHI scale and quality is hard to surpass); cardiovascular and mortality remain partially-RCT, partially-observational. Controversy rating: 3 — the field has visibly recalibrated and major guidelines align, but the historical fear has cultural inertia and the timing hypothesis has measurable skeptics; vaginal-estrogen-vs-systemic is sometimes elided in lay discussion.

Stakeholder and incentive map

• Menopause-medicine specialists (NAMS / The Menopause Society, IMS). Aligned on the timing-hypothesis recalibration; clinical and academic incentive to expand prescribing and de-stigmatize. Trial base they cite is genuine but the position is unmistakably reformist.
• Pharmaceutical industry. Significant commercial interest in MHT (estradiol, vaginal estrogen rings/tablets, combination products, novel non-hormonal vasomotor drugs like fezolinetant). Industry-funded education has rebuilt clinician engagement post-WHI.
• Primary care. Largely undertrained on MHT post-2002. Many PCPs still default to "the boxed warning is the boxed warning"; menopause-fluent care is currently a specialty referral problem.
• Oncology and breast-cancer-survivor community. Conservative; the persistent E+P signal in WHI and CGHFBC keeps the breast cancer concern alive. The estrogen-alone reduction is not yet widely internalized in lay messaging.
• Cardiovascular community. Recalibrating toward the timing hypothesis but historically wary; pharmacovigilance about VTE and stroke remains active.
• FDA / regulatory. The 2025 action is a notable institutional pivot — the agency rarely re-opens a boxed warning. The reconsideration is targeted at the inappropriate class-extension to vaginal estrogen and the over-broad systemic warnings derived from older-cohort data FDA 2025.
• Lay menopause-advocacy movement. A genuine consumer-led push (books, podcasts, social media) demanding access to MHT; sometimes oversells the case (e.g., framing MHT as universal prevention rather than symptom-driven treatment).
• Skeptic counter-incentive. Academic statisticians and some epidemiologists urging caution on the timing hypothesis given the observational nature of the strongest re-analyses; the credibility-range skeptic case above is theirs.

Population variability

• Time since menopause. The single biggest moderator. <10 years: favourable risk-benefit. >10 years or age 60+: shifts unfavourable, especially for cardiovascular and dementia outcomes Rossouw 2007 Hodis 2016.
• Uterus status. Hysterectomized women receive estrogen alone, and have the most favourable WHI outcomes (including reduced breast cancer mortality) Anderson 2004.
• Premature/surgical menopause. Stronger case for MHT through age 51 — withholding is a different harm profile from non-treatment of natural menopause Rocca 2007.
• BMI / VTE risk. Transdermal route preferred; oral estrogen raises VTE risk additively with obesity Canonico 2007.
• Race/ethnicity. SWAN data shows African American women have longer-duration vasomotor symptoms (median ~10 years); MHT access has historically been more limited in this subgroup — a real equity gap.
• Personal/family breast cancer risk. High-risk women may still use vaginal estrogen for GSM; systemic MHT generally avoided in BRCA carriers post-prophylactic salpingo-oophorectomy except under specialist guidance.
• Cardiovascular risk profile. Higher baseline ASCVD risk → transdermal preferred, threshold for initiation higher.

Knowledge gaps

• Hard cardiovascular endpoint RCT in the early-postmenopausal population. The timing hypothesis rests on age-stratified WHI re-analysis plus modest-sized RCTs (DOPS, ELITE, KEEPS); a definitive RCT with MI/stroke as primary endpoint has never been run.
• Micronized progesterone vs MPA breast safety. Observational data suggests micronized progesterone is safer, but no RCT has compared head-to-head with cancer endpoints CGHFBC 2019.
• Cognitive effect of long-duration early-initiated MHT. WHIMSY found 7-year neutrality; longer follow-up at midlife-initiation cohorts is pending Espeland 2013.
• Levonorgestrel IUD for endometrial protection in MHT. Widely used off-label; trial data thin.
• Optimal duration. NAMS 2022 explicitly rejects fixed limits, but the lifetime-use risk-benefit balance past age 70 is sparsely studied.
• Breast cancer survivor use of vaginal estrogen. Likely safe, evidenced by observational data and physiological reasoning; no RCT.
• FDA 2025 outcome. Whether the boxed warning is removed, modified, or retained — and the downstream prescribing effect — is in active flux as of this writing FDA 2025.

Scope vs brief. The brief named vasomotor symptoms, bone, genitourinary tissue, cardiovascular risk, breast cancer risk, and cognition. The article covers all six explicitly, with the timing hypothesis and the 2025 FDA boxed-warning reconsideration as the structural spine. No silent narrowing.

Hard call on the FDA 2025 citation. As of writing (mid-2026), the FDA expert panel and the public announcement of reconsideration are documented; the boxed warning has been the subject of recent regulatory motion targeted especially at the inappropriate class-extension to vaginal estrogen products. The article phrases this as "announced reconsideration" and "the institutional movement is the news" to avoid overstating finality. If by the time this entry ships the boxed warning has been formally modified or removed, the relevant sentences should be tightened to reflect the action taken.

Hard call on evidence rating (4 vs 5). Considered 5 — there is a vast trial base, and the WHI alone is one of the largest RCTs in modern medicine. Held at 4 because the timing-hypothesis cardiovascular and mortality story rests on age-stratified re-analysis plus modest-sized purpose-built RCTs (DOPS n=1006, ELITE n=643). A dedicated hard-CV-endpoint RCT in the early-postmenopausal woman has never been run; the field is currently using stratified subgroup signals to drive practice. Rating 5 would imply that question is closed; it is not.

Hard call on controversy (3). The field's major bodies have aligned (NAMS 2022, Endocrine Society, IMS), which would argue for 2. Held at 3 because primary-care and lay-public framing still trails the specialist consensus by a wide margin, and the timing-hypothesis evidence has measurable academic skeptics. The post-WHI cultural inertia is a real signal of unresolved disagreement.

Hard call on longevity (3). Considered 2 because the WHI 18-year follow-up showed no all-cause mortality signal either direction Manson 2017. Held at 3 because the proven hip-fracture reduction in primary prevention is a longevity-relevant outcome on its own, and the early-starter Bayesian meta-analysis and Danish DOPS results land favourably even if the WHI long-run average is neutral. The Rocca 2007 premature-menopause signal further argues 3 is the honest read.

Contraindications token mapping. The catalogue's closed-vocabulary contraindication tokens (cardiac-condition, blood-thinners, pregnancy) do not include "personal breast cancer history" or "history of venous thromboembolism" — the actual hard MHT contraindications. Mapped to the closest available tokens. The article's contraindications section names the real list (breast cancer history, VTE history, stroke, MI, active liver disease, unexplained bleeding) in prose, which is the surface a reader actually reads. Flagging that the closed-vocabulary list could usefully be extended with `estrogen-sensitive-cancer-history` and `venous-thromboembolism-history` for this and adjacent entries.

Separate-entry candidates. Fezolinetant and the SSRI/SNRI / gabapentin / oxybutynin non-hormonal vasomotor options are large enough to warrant their own entry. Testosterone supplementation for postmenopausal hypoactive sexual desire disorder is a distinct intervention with its own evidence base. Tibolone (not US-available) is a separate hormone with a different risk profile. Each of these is signposted in out-of-scope and would link out when the entries land.

Future-link candidates. Resistance training (bone + sarcopenia overlap), vitamin D + calcium (bone), ApoB / lipid panel (the cardiovascular risk-stratification that informs the oral-vs-patch decision), pelvic floor physiotherapy. The related field currently lists only creatine as the most-existing adjacent musculoskeletal entry; the rest are placeholders for when those entries exist.

Audience scoping. Set gender: female, ages: ["40-59", "60+"]. The 18-39 band intentionally excluded; premature menopause cases in that age range are covered in the article as a subgroup but the substance does not apply to the typical 18-39 reader.

What the article doesn't cover that a maximalist version might. Specific brand-name comparisons (Premarin vs Estrace vs branded patches), the testosterone-add story for libido, perimenopausal contraception decision-making, and full discussion of compounded "pellet" therapy. All deliberately left out — brand specifics drift, testosterone is its own entry, contraception is its own field, and pellets do not have meaningful trial support.